Century Therapeutics, Inc. (IPSC) NASDAQ

Currency In USD

Century Therapeutics, Inc.

Address

25 North 38th Street

Philadelphia, PA 19104

United States of America (the)

Phone

267 817 5790

Website

https://www.centurytx.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

June 18, 2021

Key Executives

Name	Title	Pay	Year Born
Brent Pfeiffenberger	President, Chief Executive Officer & Chairman	971,732	1978
Chad A. Cowan	Chief Scientific Officer	760,539	1972
Gregory Russotti	Chief Technology & Manufacturing Officer	789,960	1967
Krista Kauppinen	VP, General Counsel & Head of Intellectual Property	0	N/A
Michael Naso	Senior Vice President of Cell Engineering	0	N/A
Megan Bilson	Chief People Officer	0	N/A
Douglas Carr	Senior VP of Finance & Operations, Principal Financial Officer and Secretary	0	N/A
Elizabeth Devlin	Vice President & Head of Development	0	N/A

Description

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.